Clinical Trials | February 17, 2026
Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD
Duvakitug was well tolerated and safety was consistent with the induction study
Duvakitug was well tolerated and safety was consistent with the induction study
Iberdomide has the potential to be the first approved CELMoD agent
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Garijo will be the first woman to lead Sanofi in its history
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Subscribe To Our Newsletter & Stay Updated
